The DNAJC15 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line A-549, engineered for loss-of-function studies of the DNAJC15 gene. This product provides a mixed population of edited cells with targeted disruption of DNAJC15, enabling investigation of its role in mitochondrial biology and cancer metabolism without clonal selection bias. The polyclonal format allows assessment of gene function in a heterogeneous cellular context, mimicking the genetic diversity of tumor samples.
The host cell line A-549, isolated from a 58-year-old Caucasian male with lung carcinoma, is a well-established in vitro model for human lung adenocarcinoma. These cells exhibit epithelial morphology and carry a KRAS G12S driver mutation, making them particularly relevant for studying oncogenic signaling, metabolic adaptation, and drug responses in non-small cell lung cancer. A-549 cells are widely used in cancer biology, drug testing, and metabolism research due to their robust growth and well-characterized biology.
DNAJC15, also known as MCJ, is a mitochondrial co-chaperone that negatively regulates complex I of the electron transport chain, suppressing oxidative phosphorylation and ATP production. It interacts with HSPA9, TIMM44, and TIMM17A to modulate complex I assembly and activity. Its expression is upregulated by MYC and HIF1?? under oxidative stress or nutrient deprivation, leading to reduced mitochondrial respiration, increased ROS, and altered membrane potential. Downstream, DNAJC15 influences ATP synthesis, NDUFV1 and NDUFS1 functions, and apoptotic regulators BCL2 and CASP3, positioning it as a critical node in metabolism and cell death.
In the context of A-549 lung adenocarcinoma cells, DNAJC15 knockout is expected to de-repress mitochondrial complex I activity, enhancing oxidative phosphorylation and ATP generation while reducing ROS levels. This metabolic shift may alter the proliferative and survival capacity of KRAS-driven cancer cells, potentially affecting sensitivity to chemotherapeutic agents such as cisplatin. Given DNAJC15??s association with chemoresistance in ovarian and breast cancers, this model provides a platform to dissect the interplay between mitochondrial metabolism and drug response in lung adenocarcinoma. The polyclonal nature of the knockout cells enables the study of DNAJC15 loss in a population that reflects the inherent heterogeneity of cancer cell metabolism.
Researchers can employ these cells in functional assays to explore mitochondrial biology and cancer therapeutics. Representative applications include Seahorse respirometry to measure oxygen consumption, mitochondrial complex I activity assays, ATP bioluminescence, and ROS detection. Additionally, cell viability (MTT) and caspase 3/7 activity assays enable apoptosis assessment, while cisplatin sensitivity testing probes chemoresistance roles. These applications support studies in cancer metabolism, mitochondrial dysfunction, and overcoming drug resistance. For further technical information, contact Ascent Research.
